Massachusetts Democrats despatched a second letter to Johnson & Johnson’s CEO on Thursday to as soon as once more demand extra data on the shortages of kids’s Tylenol and Motrin.

Sen. Elizabeth Warren (D-Mass.) and Democrat Reps. Ayanna Pressley, Katherine Clark and Lori Trahan despatched the second letter to Johnson & Johnson CEO and Chairman of the Board Joaquin Duato, claiming that the corporate’s preliminary response left key questions unanswered.

The group of lawmakers sent their first letter on Jan. 12, and the corporate responded on Jan. 18.

“Whereas your January 18th reply underscored your public statements about elevated manufacturing, offered perception into the dimensions up of manufacturing based mostly on forecasting fashions as early as April 2022, and clarified the timeline of communication with the FDA, key questions stay unanswered,” they wrote.

Tylenol and Motrin are each over-the-counter medicines which are generally used to alleviate ache and scale back fevers. CVS and Walgreens confirmed final month that their pharmacies have been limiting the purchases of Tylenol and Motrin attributable to elevated demand and product shortages.

This scarcity got here within the peak of the winter’s “tripledemic” storm of COVID-19, influenza and RSV infections, when demand for these merchandise was excessive.

Within the preliminary letter, the lawmakers requested Johnson & Johnson when the corporate discovered of the drugs shortages, how a lot it elevated manufacturing and when availability of the youngsters’s drugs would return to regular. The group additionally requested for accessible “regional and city-by-city” knowledge on the scarcity.

Of their second letter, the group stated the corporate didn’t present them any knowledge or reply when the drugs availability would return to regular. They urged Johnson & Johnson to supply solutions by Feb. 3.

“As Members of Congress, we’re accountable to our constituents. As they navigate this scarcity and nonetheless battle to seek out product, it’s important that we’re in a position to perceive the dimensions and scope of this challenge,” the lawmakers wrote. “That is pertinent not just for addressing the second at hand but additionally for successfully working with business in partnership with the FDA to make sure this disaster doesn’t repeat itself throughout the subsequent chilly and flu season”

Johnson & Johnson stated of their first response that their colleges had been operating 24 hours a day, seven days per week since April 2022 to satisfy the winter demand, which resulted in a 50 % enhance in manufacturing year-over-year. The corporate added that they’ve additionally been in weekly communication with the Meals and Drug Administration over the difficulty since Dec. 7.

The Johnson & Johnson spokesperson stated within the letter that declining charges of fevers is a “optimistic growth” to revive stock.

“We take this matter very severely and share your concern that oldsters, households, and caregivers – and most of all infants and youngsters – could not have prepared entry to the merchandise they want,” the spokesperson wrote. “Happily, the newest epidemiological insights present a lower in incidences of fever over the past three weeks, which ought to be a optimistic growth for future retail stock restoration.”